Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 39Lymphoid 25Myeloid 19Gastrointestinal 6Thoracic 5Sarcoma 2Head & Neck 2Breast 2Plasma cell 1Gynecologic 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Thyroid Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ponatinib × Head & Neck × Clear all
NCT01838642 2017-02-15

Ponatinib for Advanced Medullary Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
3 enrolled 13 charts
Head & Neck

Thyroid Neoplasms

NCT01761747 2014-12-23

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Dana-Farber Cancer Institute

Phase 2/3 Terminated
3 enrolled 9 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡